Unknown

Dataset Information

0

Gilteritinib in the treatment of relapsed and refractory acute myeloid leukemia with a FLT3 mutation.


ABSTRACT: Acute myeloid leukemia (AML) is a malignancy of uncontrolled proliferation of immature myeloid blasts characterized by clonal evolution and genetic heterogeneity. FMS-like tyrosine kinase 3 (FLT3) mutations occur in up to a third of AML cases and are associated with highly proliferative disease, shorter duration of remission, and increased rates of disease relapse. The known impact of activating mutations in FLT3 in AML on disease pathogenesis, prognosis, and response to therapy has led to the development of tyrosine kinase inhibitors targeting FLT3. Gilteritinib is a potent, second generation inhibitor of both FLT3 and AXL, designed to address the limitations of other FLT3 inhibitors, particularly in targeting mechanisms of resistance to other drugs. In this review, we present comprehensive data on recent and ongoing studies evaluating the role of gilteritinib in the relapsed and refractory FLT3 mutated AML setting.

SUBMITTER: Chew S 

PROVIDER: S-EPMC7271272 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

altmetric image

Publications

Gilteritinib in the treatment of relapsed and refractory acute myeloid leukemia with a FLT3 mutation.

Chew Serena S   Mackey Melissa C MC   Jabbour Elias E  

Therapeutic advances in hematology 20200603


Acute myeloid leukemia (AML) is a malignancy of uncontrolled proliferation of immature myeloid blasts characterized by clonal evolution and genetic heterogeneity. FMS-like tyrosine kinase 3 (FLT3) mutations occur in up to a third of AML cases and are associated with highly proliferative disease, shorter duration of remission, and increased rates of disease relapse. The known impact of activating mutations in FLT3 in AML on disease pathogenesis, prognosis, and response to therapy has led to the d  ...[more]

Similar Datasets

| S-EPMC9746764 | biostudies-literature
| S-EPMC8506653 | biostudies-literature
| S-EPMC7897940 | biostudies-literature
| S-EPMC8171365 | biostudies-literature
| S-EPMC9151663 | biostudies-literature
| S-EPMC10468783 | biostudies-literature
| S-EPMC9153013 | biostudies-literature
| S-EPMC9179309 | biostudies-literature
| S-EPMC6172068 | biostudies-literature
| S-EPMC7189289 | biostudies-literature